



FOR IMMEDIATE RELEASE

Sustained Nano Systems, LLC appoints Michael P. Goodman as Chief Financial Officer and Jan S. Peterson as Senior Regulatory Affairs Director.

New York, NY – October 12, 2018 (NEWSFRONT MEDIA). Sustained Nano Systems, LLC, (“SNS”), a biopharmaceutical company utilizing bio-resorbable nano and microparticles for long term drug delivery, is pleased to announce the appointments of Michael P. Goodman as Chief Financial Officer and Jan S. Peterson, as Senior Regulatory Affairs Manager.

Dr. Barry Libin, CEO of SNS, said of the new appointments, “With the continued growth and success of SNS research, enabling the company to enter its clinical stages, the need for increased expertise and guidance became significant. We are most fortunate to bring on board two individuals with great experience and proficiency to help us continue advancing the company toward its goals of improving the lives of patients while rewarding the investors who have placed their confidence in our leadership.”

Michael Goodman, CPA, as Chief Financial Officer, is a former Janover LLC, Managing Partner where he provided corporate structure services for over 35 years. Known throughout the public accounting community for his creativity, Michael's depth of knowledge has translated into effective corporate strategies. In assuming overall responsibility for managing the company's finances, he will assume direct involvement with financial planning, management of financial risks, and assist in all strategic and tactical matters relating to budget management, cost–benefit analysis, forecasting needs and securing of new funding. Michael is a member of the American Institute of CPAs and the New York State Society of CPAs. He has lectured widely throughout the country on taxation issues, and has been interviewed in a number of industry-related articles in leading publications. Prior to joining Janover, Michael practiced engineering in the aerospace industry, joining the development team at Grumman in designing the propulsion system of the lunar module. Michael earned his BS in Mechanical Engineering from Lehigh University, an MS in Mechanical Engineering from The City University of New York, and an MBA from Pace University.

Jan Peterson, MS, as Senior Regulatory Affairs Director, will be responsible for overall relationships with the FDA. For the past 18 years, Jan worked at the Emmes Corporation, and has over 40 years of experience in clinical research trial design and management as well as preclinical laboratory research, data management, scientific writing, quality assurance (QA) and regulatory affairs. At Emmes, he was Director of Regulatory Affairs for numerous clinical trials sponsored by Government and commercial concerns, conducting clinical trial audit operations in 15 countries and providing strategic advice on regulatory affairs for drug and medical device development, writing clinical study reports, conducting quality assurance audits, supervising process development, and preparing regulatory documents for submission to FDA. He directed regulatory affairs for intramural and extramural clinical research trials performed under contract for the National Eye Institute (NEI), as well as commercially sponsored trials in ophthalmology. Mr. Peterson's earlier career was based in academic settings at the University of Minnesota and the University of California at San Francisco, supporting both nonclinical and clinical neurophysiology and ocular pharmacology research. He has published or presented over 50 research papers on diverse topics including ocular pharmacology and physiology, surgical treatments for glaucoma and ocular refractive errors, retinal degenerative disorders, and uveitis, as well as urology, clinical research quality auditing, regulatory affairs and good clinical practices. Mr. Peterson is the 2018 Chair of the Association of Clinical Research Professionals (ACRP) Regulatory Affairs Committee, and a participant on industry-FDA standards development committees since 2004, including an American National Standards Institute (ANSI) Z80 subcommittee for ophthalmic medical devices. He has directed and monitored multi-national trials for the successful FDA approval of ophthalmic laser products for both refractive surgery and glaucoma. Mr. Peterson received his BA in Biomedical Sciences from St. Cloud State University (MN) and his MS in Pharmacology and Experimental Therapeutics from the University of California at San Francisco.

ABOUT SUSTAINED NANO SYSTEMS (SNS)

SNS is a privately held biopharmaceutical clinical phase company focused on the development and commercialization of innovative therapies for diseases and conditions in ophthalmology, oncology and other areas. The Company's research facility is located on the campus of Stony Brook University as part of the Long Island High Technology Incubator. The SNS platform is the result of a comprehensive research effort that allows for long term micro-dosing for the continuous release of drugs to targeted tissues as prescribed. The basis of the SNS pipeline is its patented technology that incorporates bio-resorbable nano and micro carriers to deliver a wide variety of drugs that offer both enhanced drug release kinetics and high dose capacity. Such drug delivery is especially needed in ophthalmology, oncology, inflammatory conditions, neurologic disorders, and dermatology.

For further information, visit: www.sustainednanosystems.net

Forward-Looking Statements

SNS Disclosure Notice: This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "should," "would," "estimate," or "continue," or the negative or other variations thereof or comparable terminology are intended to identify forward looking statements. Investors are cautioned that all forward looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense

costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company's ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company's control.

Investors are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.

Contact:
Dr. Barry Libin
[\(516\) 353-7983](tel:5163537983)
barlibin@gmail.com

Media Relations
info@newsfrontmedia.com

You are subscribed to Sustained Nano Systems, LLC Investor Relations e-mail alerts:
To unsubscribe please send to info@newsfrontmedia.com